RxDoctor Payments Data

Robert Knear-Bell, MD

Family Medicine · Wilmington, NCNPI 1033613443

Payments from drug & device makers

$684in general payments, 2019–2025

Across 19 payments — averaging $36.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$265
  • Novo Nordisk$117
  • Biotronik NRO, Inc.$85
  • Exact Sciences$68
  • Gilead$30
  • Genentech USA, Inc.$27
  • plus $92 from 4 others

What the payments were for

  • Food & beverage$684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$66,743
Medicare patients
261
Services billed
665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$40,595
JardianceEmpagliflozin25$40,345
FarxigaDapagliflozin Propanediol17$28,505
MounjaroTirzepatide24$27,667
OzempicSemaglutide25$24,675
TrulicityDulaglutide13$22,304
Atorvastatin Calcium303$7,236
Ezetimibe59$2,720
Irbesartan58$2,509
Fluticasone Propionate HfaFluticasone Propionate13$1,918
Olmesartan Medoxomil34$1,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,740
Lisinopril100$1,433
Simvastatin47$1,432
Fluoxetine Hcl17$1,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$265$49,97037 claims
PfizerEliquis$19$40,59541 claims
Boehringer IngelheimJardiance$23$40,34525 claims
Novo NordiskOzempic$117$24,67525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →